Pharmafile.com’s weekly COVID-19 news round-up
pharmafile | May 6, 2020 | News story | Research and Development | COVID-19, coronavirus
Vaccines and treatments for COVID-19 continue to dominate the news, as two studies reveal “positive” data for Gilead’s remdesivir in hospitalised coronavirus patients while Lonza and Moderna have entered an agreement to mass produce a vaccine.
In other news, scientists expect the global pandemic to last as long as two years and believe it will not be properly under control until two-thirds of the world are immunised.
1. Arizona GOP lawmakers and AAPS say hydroxychloroquine has 90% chance of helping COVID-19 patients, but data is not based on clinical trials – Published 29/04/2020
The Association of American Physicians and Surgeons (AAPS) wrote a letter to Republican Arizona Governor Doug Ducey urging the wider use of hydroxychloroquine, based on data they have collected.
2. Two studies reveal “positive” data for Gilead’s remdesivir in hospitalised COVID-19 patients – Published 30/04/3030
The first findings of two new studies have been revealed, detailing the efficacy of Gilead’s antiviral therapy remdesivir in the treatment of patients hospitalised with COVID-19.
3. Lonza and Moderna enter agreement to mass produce coronavirus vaccine – Published 04/05/2020
Lonza Group AG and Moderna Inc have entered a deal to develop 1 billion doses of coronavirus vaccines a year.
4. COVID-19 pandemic likely to last two years, study says – Published 01/05/2020
The coronavirus pandemic is likely to last as long as two years and will not be properly controlled until two-thirds of the world’s populations have become immune.
5. AstraZeneca joins forces with University of Oxford to develop and manufacture potential coronavirus vaccine – Published on 30/04/2020
A “landmark” partnership has been struck between AstraZeneca and the University of Oxford in the ongoing battle against COVID-19, with the former agreeing to aid in the development and large-scale manufacture of the latter’s potential recombinant adenovirus vaccine for the prevention of novel coronavirus infection.
Related Content
COVID-19 vaccine eligibility creates challenges for UK pharmacies
Pharmacists across England have reported widespread confusion among patients attempting to book COVID-19 vaccination appointments …
Mental health medicine use in England reaches record high, NHSBSA report reveals
According to new data published by the NHS Business Services Authority (NHSBSA), mental health prescriptions …
FDA approves Moderna’s Spikevax for children at increased risk of COVID-19
Moderna has been granted US Food and Drug Administration (FDA) approval for its COVID-19 vaccine, …
